Case study: Identifying allosteric modulators for GPCRs
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
List view / Grid view
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
According to new research, the bioactive compound of ginger root, 6-gingerol, prevented disease progression of lupus in mice.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.